Selected Papers from Vaccines Summit Boston 2022
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 August 2022) | Viewed by 334
Special Issue Editor
Interests: Mycobacterium tuberculosis genetics; mycobacteriophages; persistence-the capacity of M. tuberculosis to resist sterilization, vaccines for Tuberculosis, Influenza, Herpes, and Dengue
Special Issue Information
Dear Colleagues,
This Special Issue contains a selection of papers presented at the Vaccines Summit Boston 2022 which will be held on March 28–31, 2022 Virtual. This Special Issue will highlight the current advances in vaccines, vaccination and immunology. It brings together leading biotech and pharma industry experts, academicians, and decision makers who are passionate about addressing major global issues by turning ideas into solutions.
This Special Issue covers the following topics: Novel Live Attenuated Vaccines; Cancer Vaccines; HIV Vaccine; COVID-19 Vaccine R&D; Influenza & Respiratory; Bacterial Vaccines; Emerging & Re-Emerging Diseases; Bioprocessing & Manufacturing; Clinical Trials; Vaccines Safety; Immune Profiling; New Vaccine Development; Vaccine Adjuvants; DNA & RNA Vaccines; Malarial Vaccines; Subunit Vaccines.
Selected extended papers from this conference can be submitted to the conference Special Issue with a 25% discount on the article processing charge. We look forward to your submission.
Dr. William R. Jacobs
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel live attenuated vaccines
- cancer vaccines
- HIV vaccine
- COVID-19 vaccine R&D
- influenza & respiratory
- bacterial vaccines
- emerging & re-emerging diseases
- bioprocessing & manufacturing
- clinical trials
- vaccines safety
- immune profiling
- new vaccine development
- vaccine adjuvants
- DNA & RNA vaccines
- malarial vaccines
- subunit vaccines
